In yesterday’s Wall Street session, Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares traded at $11.40, up 2.24% from the previous session.
16 analysts cover Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $10.00, we find $14.50. Given the previous closing price of $11.15, this indicates a potential upside of 30.04 percent. ICPT stock price is now -9.19% away from the 50-day moving average and -24.08% away from the 200-day moving average. The market capitalization of the company currently stands at $481.08M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 9 analysts and a buy rating from 4. Brokers who have rated the stock have averaged $15.25 as their price target over the next twelve months.
With the price target enhanced from $8 to $19, H.C. Wainwright Upgraded its rating from Sell to Buy for Intercept Pharmaceuticals Inc. (NASDAQ: ICPT).
Insiders disposed of 24,566 shares of company stock worth roughly $0.28 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ICPT stock. A new stake in Intercept Pharmaceuticals Inc. shares was purchased by ADAGE CAPITAL PARTNERS GP, L.L.C. during the first quarter worth $4,998,000. PRUDENTIAL FINANCIAL INC invested $2,569,000 in shares of ICPT during the first quarter. In the first quarter, MARSHALL WACE, LLP acquired a new stake in Intercept Pharmaceuticals Inc. valued at approximately $1,292,000. JANE STREET GROUP, LLC acquired a new stake in ICPT for approximately $992,000. PROFUND ADVISORS LLC purchased a new stake in ICPT valued at around $545,000 in the second quarter. In total, there are 228 active investors with 80.60% ownership of the company’s stock.
On Thursday morning Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) stock kicked off with the opening price of $12.00. During the past 12 months, Intercept Pharmaceuticals Inc. has had a low of $8.82 and a high of $21.86. As of last week, the company has a debt-to-equity ratio of 4.96, a current ratio of 2.40, and a quick ratio of 2.40. The fifty day moving average price for ICPT is $12.36 and a two-hundred day moving average price translates $14.99 for the stock.
The latest earnings results from Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.77, missing analysts’ expectations of -$0.65 by -0.12. This compares to $0.54 EPS in the same period last year. The net profit margin was 70.30% and return on equity was -812.50% for ICPT. The company reported revenue of $67.96 million for the quarter, compared to $59.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.9 percent. For the current quarter, analysts expect ICPT to generate $79.31M in revenue.
Intercept Pharmaceuticals Inc.(ICPT) Company Profile
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.
